FDA's Oncology Center of Excellence, its new face for oncology drug development, is now officially on the agency organization chart.
OCE is on par with Center for Drug Evaluation and Research (CDER), as well as the biologics and device centers,...
FDA's Oncology Center Of Excellence On Equal Terms With CDER In New Org Chart
Listen to this article
While OCE has a lofty status, it has yet to gain a large cadre of staff.
Learn what's happening at the US FDA. On the go.
More from US FDA
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
- • By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
- • By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
More from Agency Leadership
- • By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
- • By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
